Efficacy and safety profile of busulfan plus low-dose melphalan (BUMEL) versus high-dose melphalan (MEL200) as a conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma patients: a systematic review and meta-analysis
HematologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Expert review of hematology
- Publicado em
- 24 mar 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and safety profile of busulfan plus low-dose melphalan (BUMEL) versus high-dose melphalan (MEL200) as a conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma patients: a systematic review and meta-analysis
Shahzaib Maqbool, Imran Khan, Muhammad Ibrahim, Aye Mon Thida, Muhamamd Salman Faisal, Fatima Faraz, Abat Khan, Moazzam Shahzad, Mohammad Ebad Ur Rehman, Qurat Ul Ain Muhammad et al.
Descritores MeSH
- Transplantation Conditioning
- Busulfan
- Multiple Myeloma
- Hematopoietic Stem Cell Transplantation
- Antineoplastic Combined Chemotherapy Protocols
- Melphalan
- Humans
- Transplantation, Autologous
- Treatment Outcome